Reported Saturday, Merck’s Remigromig Delivers Mean BCVA Gains Of 9.1 Letters At 0.5 Mg And 8.7 Letters At 0.8 Mg Versus 11.8 For Ranibizumab, Meeting Non-Inferiority, With No Secondary Endpoint Showing Superiority
Reported Saturday, Merck’s Remigromig Delivers Mean BCVA Gains Of 9.1 Letters At 0.5 Mg And 8.7 Letters At 0.8 Mg Versus 11.8 For Ranibizumab, Meeting Non-Inferiority, With No Secondary Endpoint Showing Superiority
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed